caa a22 4500 445333367 CHVBK 20180317142744.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1245/s10434-011-1561-2 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1561-2 Salinomycin Selectively Targets ‘CD133+' Cell Subpopulations and Decreases Malignant Traits in Colorectal Cancer Lines [Elektronische Daten] [Tao-Tao Dong, Hou-Min Zhou, Lin-Lin Wang, Bo Feng, Bo Lv, Min-Hua Zheng] Background: Cancer stem-like cells (CSCs) in colorectal cancers (CRC) may account for the failure of treatments because they are resistant to many current anticancer therapies. Salinomycin, a potassium ionophore, was recently identified as a selective inhibitor of breast CSCs. Methods: The human CRC cell lines HT29 and SW480 were treated with salinomycin and oxaliplatin. Cell viability was determined with cell counting kit 8. Fraction of CD133+ cell subpopulations was assessed by Flow Cytometric analysis. Clonogenecity and migration were determined with soft agar and Boyden chamber assays. Molecular changes were assessed by immunofluorescence staining, RT-PCR, and Western blot analysis. Results: We report that salinomycin reduces the proportion of CD133+ subpopulations in human CRC HT29 and SW480 cells. Furthermore, salinomycin treatment decreases colony-forming ability and cell motility in HT29 cells. Moreover, salinomycin downregulates the expression of vimentin and induces the E-cadherin expression in HT29 cells. Conclusions: This study demonstrates the ability of salinomycin to selectively target "CD133+” cell subpopulations and decrease the malignant traits in colorectal cancer lines. Society of Surgical Oncology, 2011 Dong Tao-Tao Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China aut Zhou Hou-Min Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China aut Wang Lin-Lin Shanghai Jiaotong University School of Medicine, Shanghai, China aut Feng Bo Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China aut Lv Bo Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China aut Zheng Min-Hua Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China aut Annals of Surgical Oncology Springer-Verlag 18/6(2011-06-01), 1797-1804 1068-9265 18:6<1797 2011 18 10434 https://doi.org/10.1245/s10434-011-1561-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1561-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Dong Tao-Tao Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Zhou Hou-Min Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Wang Lin-Lin Shanghai Jiaotong University School of Medicine, Shanghai, China aut NATIONALLICENCE 700 1- Feng Bo Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Lv Bo Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Zheng Min-Hua Department of Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/6(2011-06-01), 1797-1804 1068-9265 18:6<1797 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer